Comparative clinical efficacy of acupuncture-related therapies for ulcerative colitis: a systematic review and network meta-analysis Authors: Longtao Zhang, Yanxiao Sun, Ziyang Ru, Dan Li, Yuxia Ma Published: 2025 ABSTRACT BackgroundUlcerative colitis (UC) is a chronic and recurrent inflammatory bowel disease. Current drug treatments are often associated with side effects, unstable efficacy, and high relapse rates. Therefore, exploring complementary and alternative therapies such as acupuncture is of significant importance for optimizing UC clinical management strategies. This study employs a network meta-analysis method to systematically compare the efficacy and safety of various acupuncture-related therapies in treating UC, aiming to provide evidence-based guidance for selecting the optimal clinical intervention.MethodsWe systematically searched 8 databases for randomized controlled trials (RCTs) of acupuncture-related therapies for ulcerative colitis, including China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, China Biological Medicine (CBM), PubMed, EMbase, the Cochrane Library, and Web of Science. The total effective rate, Mayo score, Baron endoscopic score were used for primary outcomes, interleukin-6 (IL-6) levels, tumor necrosis factor-alpha (TNF-α) levels, and relapse rate were selected as secondary outcomes. The Cochrane risk of bias tool (RoB 2.0) was used to assess the quality of the articles, and StataMP 18 was used for statistical analysis. Heterogeneity and consistency were assessed, and the comparative effectiveness of different acupuncture interventions was ranked using Surface under the cumulative ranking curve (SUCRA).ResultsA total of 76 RCTs were included, involving 7,484 participants. Auricular acupressure combined with Chinese herbal medicine (AA + CHM) (RR 1.71, 95% CI: 1.47, 1.99, SUCRA = 99.9%) was shown to have effective to improving total effective rate. For Mayo score, the most effective intervention was acupuncture combination therapy (ACU-CT) (SMD –4.85, 95% CI: –6.66, –3.05, SUCRA = 97.5%). In terms of reducing Baron endoscopic score, ACU-CT (SMD-2.31, 95% CI: –3.81, –0.81, SUCRA = 84.1%) had the best efficacy. For IL-6 levels, warm acupuncture (WA) (SMD –3.10, 95% CI: –4.56, –1.65, SUCRA = 96.1%) showed the best efficacy. For TNF-α levels, warm acupuncture combination therapy (WA-CT) (SMD –2.32, 95% CI: –4.54, –0.10, SUCRA = 76.8%) demonstrated the best efficacy. For recurrence rate, Acupuncture (ACU) (OR 0.15, 95% CI: 0.03, 0.65, SUCRA = 89.3%) achieved the greatest reductions. SUCRA analysis showed that WA, ACU-CT, WA-CT, and acupoint catgut embedding (ACE) ranked highest in most of the outcomes. Acupoint frequency statistics revealed that the most commonly used acupoints for treating UC were Tianshu (ST25), Zusanli (ST36), Shangjuxu (ST37), Zhongwan (CV12), Guanyuan (CV4), Dachangshu (BL25), Pishu (BL20), Shenque (CV8), Qihai (CV6), and Sanyinjiao (SP6).ConclusionThese findings may provide preliminary evidence-based guidance for acupuncture-related interventions as a potential complementary or alternative treatment for patients with UC, particularly those who have poor responses to conventional pharmaceutical treatment. In the future, more large-sample, high-quality RCTs are needed to further confirm the long-term efficacy and mechanisms of different acupuncture interventions.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251082924. Introduction Ulcerative colitis (UC) is a chronic immune-mediated inflammatory bowel disease (IBD) characterized by persistent inflammation of the colonic and rectal mucosa, often manifests clinically with diarrhea, abdominal pain, bloodymucopurulent, and tenesmus (1, 2). The global prevalence of UC reached 5 million cases in 2023 (2). With changes in the environment, dietary structure, and lifestyle, the incidence and prevalence of UC have been rising annually, particularly in developed countries. With the increasing disease burden, this trend has been extended to traditionally low-incidence regions that are undergoing industrialization (3, 4). Data indicate that UC patients face a 4.5% risk of developing colorectal cancer within 20 years of diagnosis (5), which is 2–3 times higher than that of the general population (6). Furthermore, UC not only causes gastrointestinal symptoms but is also frequently associated with chronic pain, anxiety, and depression, significantly reducing quality of life (7). Traditional treatments include 5-aminosalicylic acid (5-ASA), corticosteroids, immunomodulators, and biologics (8, 9). While these medications can control inflammation in the short term, they are associated with significant side effects, unstable efficacy, high relapse rates, and drug dependence. For example, 5-ASA may cause gastrointestinal symptoms such as headaches and nausea, and in severe cases, it can lead to interstitial nephritis and other nephrotoxic reactions; Common side effects of corticosteroids include hyperglycemia, osteoporosis, and an increased risk of infection; Immunomodulators are associated with potential adverse effects such as myelosuppression and hepatotoxicity; Biologics carry risks of serious adverse effects, such as serious infections, reactivation of tuberculosis, and lymphoma (10–12). Long-term medication poses safety risks and increases the financial burden on patients. These limitations underscore the pressing need for improved and more effective therapeutic strategies in the management of ulcerative colitis. Given the limitations of conventional pharmacotherapy, there is a pressing clinical need to explore complementary and alternative treatment options for UC. Acupuncture, a cornerstone of Traditional Chinese Medicine (TCM), was selected for this network meta-analysis for several compelling reasons. First, from a TCM theoretical perspective, the clinical manifestations of UC closely align with syndromes such as “dysentery” and “abdominal pain,” which are traditionally attributed to damp-heat, spleen-kidney deficiency, and qi stagnation. Acupuncture, through stimulation of specific acupoints, is believed to regulate the flow of Qi and Blood, clear damp-heat, and strengthen the spleen and kidney, thereby addressing the fundamental TCM pathological patterns underlying UC. Furthermore, acupuncture has attracted increasing attention due to its favorable safety profile and multi-target regulatory potential. Clinical studies have shown that acupuncture can alleviate UC symptoms, improve intestinal function, reduce inflammation, and enhance quality of life (13–15). Multiple studies have confirmed that acupuncture therapy can improve the intestinal mucosal microenvironment by modulating the balance of pro-inflammatory and anti-inflammatory factors such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) (16). It can also stimulate specific acupoints to modulate the balance of gut microbiota and regulate gut-brain axis function (17). Furthermore, acupuncture has been shown to inhibit fibrosis and promote epithelial regeneration, as well as to regulate gut microbiota balance (18). Moxibustion can enhance mucosal immune function and promote tissue repair (19). Therefore, a systematic comparison of the relative effectiveness of different acupuncture-related modalities is highly relevant for informing clinical practice and guiding future research. A diverse range of acupuncture-related therapies is commonly used in clinical practice for UC, primarily including the following modalities: Acupuncture involves the insertion of fine, sterile needles into specific acupoints. Warm acupuncture integrates needle insertion with the burning of moxa on the needle handle to deliver combined needling and thermal stimulation. Electroacupuncture applies a mild electric current through inserted needles to provide continuous stimulation. Moxibustion stimulates acupoints primarily via thermal energy generated by burning moxa (a therapeutic material derived from the dried wool of the mugwort plant, Artemisia argyi), either directly or indirectly atop an insulating medium. Acupoint Catgut Embedding entails the subcutaneous implantation of absorbable sutures at acupoints to provoke a sustained, mild stimulatory effect. Auricular acupressure involves the application of seeds or magnetic beads on specific ear acupoints, which patients are instructed to press periodically for self-stimulation. However, due to the diversity of acupuncture-related therapies, differing focuses on efficacy, and inconsistent conclusions, previous systematic reviews and meta-analyses (20–23) have only compared single control groups and lack clinical evidence for direct comparisons of efficacy between different acupuncture-related therapies. Therefore, this study employs a network meta-analysis approach to compare the efficacy and safety of various acupuncture-related therapies in the treatment of UC, aiming to provide evidence-based guidance for the use of Traditional Chinese Medicine in treating UC. Methods The protocol for this systematic review and network meta-analysis has been registered in PROSPERO (CRD420251082924). This study followed the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the PRISMA extension statement for network meta-analyses (PRISMA-NMA) (24, 25), as detailed in Supplementary Material 1. Search strategy We searched PubMed, Embase, the Cochrane Library, Web of Science, CBM, CNKI, Wanfang, and VIP databases from inception to June 15, 2025. The search was conducted using a combination of subject headings and free words, and the language was limited to Chinese and English. Search keywords include terms such as “acupuncture, electroacupuncture, warm needling, moxibustion, ulcerative colitis, randomized controlled trials.” Additionally, relevant conference proceedings and clinical trial registries were searched for gray literature. A detailed search strategy is provided in Supplementary Material 2. Inclusion and exclusion criteria Inclusion criteria (1) S (Study design): Published literature of RCTs, including English and Chinese publications; S (Study design): Published literature of RCTs, including English and Chinese publications; (2) P (Participants): Patients with a clear diagnosis of UC, regardless of gender, age, and course of the disease. The clinical diagnostic criteria of UC are mainly combined with clinical manifestations, endoscopy, histopathology, and laboratory tests; P (Participants): Patients with a clear diagnosis of UC, regardless of gender, age, and course of the disease. The clinical diagnostic criteria of UC are mainly combined with clinical manifestations, endoscopy, histopathology, and laboratory tests; (3) I (Interventions): The intervention group was composed of various acupuncture-related therapies, including acupuncture (ACU), warm acupuncture (WA), electroacupuncture (EA), moxibustion (MOX), acupoint catgut embedding (ACE), and auricular acupressure (AA). These therapies can be used alone, in combination, or in conjunction with the control group. Combination therapy (CT) included auricular acupressure combined with Chinese herbal medicine (AA + CHM); acupuncture combination therapy (ACU-CT); moxibustion combination therapy (MOX-CT); warm acupuncture combination therapy (WA-CT); acupoint catgut embedding combination therapy (ACE-CT); electroacupuncture combination therapy (EA-CT); I (Interventions): The intervention group was composed of various acupuncture-related therapies, including acupuncture (ACU), warm acupuncture (WA), electroacupuncture (EA), moxibustion (MOX), acupoint catgut embedding (ACE), and auricular acupressure (AA). These therapies can be used alone, in combination, or in conjunction with the control group. Combination therapy (CT) included auricular acupressure combined with Chinese herbal medicine (AA + CHM); acupuncture combination therapy (ACU-CT); moxibustion combination therapy (MOX-CT); warm acupuncture combination therapy (WA-CT); acupoint catgut embedding combination therapy (ACE-CT); electroacupuncture combination therapy (EA-CT); (4) C (Comparators): The interventions in the control group included Western medicine (WM), retention enema (RE), traditional Chinese medicine (CHM) or Western medicine combined with retention enema (WM + RE); C (Comparators): The interventions in the control group included Western medicine (WM), retention enema (RE), traditional Chinese medicine (CHM) or Western medicine combined with retention enema (WM + RE); (5) O (Outcomes): Primary outcomes included total effective rate, Mayo score and Baron endoscopic score. Secondary outcomes included IL-6 levels, TNF-α levels, and recurrence rates. O (Outcomes): Primary outcomes included total effective rate, Mayo score and Baron endoscopic score. Secondary outcomes included IL-6 levels, TNF-α levels, and recurrence rates. Excluded criteria (1) Non-randomized controlled trials, such as case reports, observational studies, reviews, or animal experiments; Non-randomized controlled trials, such as case reports, observational studies, reviews, or animal experiments; (2) Studies in which patients received multiple concurrent interventions at the same time, such as psychotherapy, cupping, or scraping, or in which the control group also received acupuncture, resulting in the inability to assess the effects of acupuncture independently; Studies in which patients received multiple concurrent interventions at the same time, such as psychotherapy, cupping, or scraping, or in which the control group also received acupuncture, resulting in the inability to assess the effects of acupuncture independently; (3) Studies that failed to report original outcome data or had unclear efficacy criteria and could not be contacted for further information; Studies that failed to report original outcome data or had unclear efficacy criteria and could not be contacted for further information; (4) Studies with small sample sizes or treatment durations of < 3 weeks. Studies with small sample sizes or treatment durations of < 3 weeks. Study selection and data extraction Two researchers independently managed the literature using EndNote 20. The retrieved literatures were first deduplicated, and then titles, abstracts, and full texts were reviewed to select studies that met the inclusion criteria. Disagreements were resolved through consultation or with the assistance of a third researcher. Finally, two researchers cross-checked the literatures. After identifying the eligible studies, data extraction was performed using a pre-designed Excel spreadsheet. The extracted information included: title, first author, year of publication, sample size, age, disease duration, intervention, intervention details, duration of treatment, outcomes, and adverse events. Quality assessment Two researchers independently evaluated the risk of bias using the Cochrane risk of bias tool (RoB 2.0) (26) across five domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported results. The results of the assessment were categorized as “low risk,” “some concerns,” or “high risk.” Disagreements were resolved through discussion or by consultation with a third researcher. Certainty of evidence Two researchers assessed the certainty of evidence for the outcomes using the GRADE approach with GRADE pro GDT software (Grading of Recommendations, Assessment, Development and Evaluation) (27). The GRADE system evaluates the quality of evidence based on six domains: Study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias. The overall quality of evidence is classified into four levels: High, moderate, low, and very low. Statistical analysis Network meta-analysis was performed using StataMP 18.0. For dichotomous variables, total effective rate was expressed as the risk ratio (RR), and recurrence rate was represented by the odds ratio (OR). For continuous variables, such as Mayo score, Baron endoscopic score, IL-6, and TNF-α levels, the standardized mean difference (SMD) was used as the Effect size measure, with both expressed with 95% confidence intervals (CIs). A statistically significant difference between groups was considered when the 95% CI for dichotomous variables did not include 1 or for continuous variables did not include 0. Heterogeneity was quantified using τ2, categorized as low (< 0.04), low to moderate (0.04–0.16), moderate to high (0.16–0.36), or high (> 0.36) (28–30). Consistency between direct and indirect comparisons was evaluated using the node splitting method (31). The surface under the cumulative ranking curve (SUCRA) was used to compare the efficacy of different interventions, with a larger area indicating better efficacy of the intervention (32). Funnel plots were used to assess publication bias in the included literatures (33). Results Literature search results A total of 4183 relevant articles were retrieved through database search, 2408 duplicate articles were eliminated by Endnote 20 software, and 286 articles were obtained by reading the titles and abstracts according to the inclusion and exclusion criteria. After reading the full text, 210 articles were excluded. A total of 76 articles were finally determined to meet the inclusion criteria. The literature screening process is shown in Figure 1. Flow chart of the search for eligible RCTs. Included study characteristics A total of 76 randomized controlled trials were included in this study (13–15, 34–106), with 3,847 cases in the experimental group and 3,637 cases in the control group. The maximum sample size was 220 and the minimum was 60. The age ranged from 30 to 50 years old. The duration of treatment varied from 3 to 6 weeks. The acupuncture point selection schemes differed among the studies, with high-frequency acupoints including Tianshu (ST25), Zusanli (ST36), Shangjuxu (ST37), Zhongwan (CV12), Guanyuan (CV4), and Dachangshu (BL25). Study characteristics are summarized in Tables 1, 2. Both the acupoint frequency statistics and the standardized acupoint definitions are available in Supplementary Material 3. TABLE 1Baseline of characteristics of included studies.Study IDSample size (T/C)Age (Year, T/C)Disease duration (Year, T/C)Treatment groupControl groupDuration of treatmentOutcomesZhao 2012 (34)33/3237.48 ± 9.34 39.52 ± 8.672.33 ± 1.65 2.72 ± 1.71ACE + RERE4 weeks➀Zhang 2003 (35)43/3539.5 ± 9.25 39 ± 198.25 ± 3.88 8.25 ± 3.88ACUWM + RE4 weeks➀➅Wang 2022a (36)67/6744.27 ± 3.65 44.15 ± 3.572.61 ± 0.35 2.57 ± 0.43ACU + CHM + WMWM4 weeks➀➁Cheng 2009 (37)40/4053 ± 8.5 53 ± 8.55.84 ± 2.58 5.84 ± 2.58MOX + CHM + WMWM4 weeks➀Fan 2021 (38)45/4541.55 ± 5.56 42.38 ± 4.154.32 ± 1.03 4.67 ± 1.15MOX + CHMWM4 weeks➀➂➃➄Zhou 2008 (39)110/11048.60 ± 7.48 50.24 ± 6.954.75 ± 1.69 4.89 ± 1.76EA + MOX + WMWM6 weeks➀➅Xu 2022 (40)36/3742.05 ± 8.56 40.89 ± 9.531.12 ± 0.56 1.60 ± 0.77MOX + CHMWM4 weeks➀➂➄Zhao 2019 (41)35/3547.2 ± 6.8 42.7 ± 8.91.44 ± 0.56 1.25 ± 0.11MOXWM12 weeks➀Yang 2017 (42)30/3041.17 ± 7.43 42.25 ± 6.814.13 ± 1.26 3.84 ± 1.47MOXWM8 weeks➀➁➂He 2021 (43)48/4832.80 ± 4.80 33.70 ± 5.100.02 ± 0.01 0.02 ± 0.01MOX + REWM4 weeks➁➂➃Zhao 2018 (44)55/5546.25 ± 10.12 45.37 ± 12.462.45 ± 1.31 2.83 ± 1.72ACU + CHMWM4 weeks➀➄Zhu 2003 (45)50/2042.5 ± 11.25 43 ± 1110.5 ± 4.75 9.92 ± 4.54ACEWM4 weeks➀Sun 2017 (46)36/3643.53 ± 9.24 44.14 ± 9.476.44 ± 2.55 6.47 ± 2.51MOXWM12 weeks➀Ma 1997 (47)60/3045.5 ± 11.25 46.5 ± 23.256.75 ± 3.13 5.25 ± 2.38ACUWM4 weeks➀Wang 2006 (48)30/3040 ± 6.5/ 41 ± 6.50.5∼12 0.6∼13MOXWM4 weeks➀Li 2006 (49)56/6037.1 37.30.25∼2.33 0.25∼2ACEWM4 weeks➀Kang 2022 (50)50/5040.02 ± 9.11 39.27 ± 9.803.77 ± 1.84 3.65 ± 2.41ACU + CHMWM12 weeks➀➁➃➄Wu 2015 (51)52/5049.5 ± 7.6 48.5 ± 7.3NR NRACU + MOX + CHMCHM8 weeks➀➅Zhang 2021a (52)39/3839.4 ± 11.1 38.9 ± 10.24.23 ± 3.15 3.96 ± 2.89ACUWM8 weeks➀➂Gong 2020 (53)50/5036.2 ± 9.0 39.5 ± 8.52.3 ± 1.6 2.6 ± 1.4ACEWM6 weeks➀➃➄Feng 2020 (54)36/3631.54 ± 3.48 32.22 ± 3.975.36 ± 1.83 5.21 ± 2.13ACUWM4 weeks➀Zu 2017 (55)45/4539.56 ± 10.69 40.76 ± 11.093.11 ± 1.30 3.42 ± 1.41MOX + RE + WMWM + RE4 weeks➀➃➄Lv 2017a (56)50/5040.86 ± 10.83 41.09 ± 10.683.19 ± 1.2 3.27 ± 1.28MOX + CHM + WMWM4 weeks➀➃➄Guo 2016 (57)35/3546.25 ± 15.11 50.2 ± 14.195.08 ± 2.1 4.83 ± 1.74ACU + MOX + WMWM6 weeks➀Chen 2004 (58)100/3044.5 ± 13.25 42 ± 11.511.13 ± 5.44 10.13 ± 4.84ACEWM24 weeks➀Chang 2017 (59)45/4538.24 ± 9.79 40.01 ± 11.233.05 ± 1.20 3.16 ± 1.41MOX + RE + WMWM + RE6 weeks➀➃➄Wang 2020a (60)32/3227.24 ± 2.23 26.12 ± 5.095.77 ± 1.99 5.34 ± 2.12EA + CHM + WMWM8 weeks➀Xu 2009 (61)40/4047.37 ± 5.17 49.13 ± 4.922.79 ± 3.91 3.03 ± 4.18ACU + CHMWM6 weeks➀Gu 2016 (62)38/3740.5 ± 2.8 42.5 ± 3.24.9 ± 1.3 5.2 ± 2.12MOX + CHMWM8 weeks➀➅Zhang 2022 (13)47/4744 ± 9 46 ± 83.41 ± 0.73 3.59 ± 0.80EA + WMWM8 weeks➀➃Xie 2019 (63)65/6536 ± 8 35 ± 83.40 ± 1.03 3.34 ± 1.01ACU + CHMCHM4 weeks➀➄Shen 2019 (64)50/5037 ± 9 38 ± 100.9 ± 0.1 0.8 ± 0.1MOX + WMWM12 weeks➀➅Shen 2012 (65)33/3046 ± 7 41 ± 73.5 ± 1.3 3.8 ± 1.6ACUWM12 weeks➀Zong 2015 (66)34/3243 ± 12 42.5 ± 11.251.05 ± 0.275 3.55 ± 1.225ACEWM6 weeks➀➅Du 2008 (67)42/4046 ± 9.5 43.5 ± 9.2514.7 ± 6.65 15.75 ± 7.125ACU + RE + CHMWM + RE4 weeks➀Hou 2018 (68)48/4835.76 ± 4.53 36.27 ± 4.364.69 ± 1.21 4.73 ± 1.17MOX + WMWM4 weeks➀Ye 2024 (69)60/6039.49 ± 4.28 39.44 ± 4.383.19 ± 0.42 3.23 ± 0.39ACU + CHMWM4 weeks➀Wang 2022b (70)30/3047.22 ± 4.02 47.42 ± 4.034.55 ± 1.29 4.49 ± 1.37ACUWM4 weeks➀Du 2007 (71)89/8043.6 41.74.8 ± 1.4 4.7 ± 2.1AA + CHMWM4 weeks➀Cong 2018 (72)75/7238.61 ± 11.74 37.82 ± 12.673.75 ± 2.81 3.61 ± 2.47ACU + CHMWM6 weeks➀➁➃➄Zhou 2003 (73)34/3238.5 ± 9.75 38.5 ± 9.755 ± 1.5 5 ± 1.5MOXWM4 weeks➀Ge 2014 (74)31/3135.6 ± 7.5 38.4 ± 7.83.7 ± 2.8 4.0 ± 2.5EA + WMWM8 weeks➀Zhang 2012 (75)45/4537.63 ± 8.71 35.27 ± 8.566.32 ± 3.11 6.95 ± 3.23ACU + REWM4 weeks➀Chen 2013 (76)40/4047.5 ± 12.25 46.5 ± 13.758.5 ± 3.25 9.5 ± 4.25MOX + RE + WMWM + RE4 weeks➀➅Xu 2023 (77)50/5139.54 ± 4.52 39.66 ± 4.491.99 ± 0.47 1.96 ± 0.50ACU + CHM + RERE4 weeks➀➁➅Wang 2020b (78)36/3635.0 ± 3.2 34.8 ± 2.97.0 ± 2.1 6.9 ± 1.8ACU + CHM + WMWM6 weeks➀Teng 2014 (79)40/4038.5 ± 8.75 39.5 ± 8.755.2 ± 2.4 5.75 ± 2.625EA + RE + WMWM8 weeks➀Zhang 2009 (80)50/4040.73 ± 8.1 38.73 ± 7.54.2 ± 1.2 4.1 ± 1.7ACU + CHMWM4 weeks➀➅Cao 2001 (81)40/4050 ± 14 47.5 ± 13.754.21 ± 1.90 4.25 ± 1.875ACU + REWM + RE6 weeks➀Bao 2014 (82)50/5041. .2 ± 6. 7 42. .40. 3 ± 5. 74. 3 ± 1. 2 4. 5 ± 1. 6ACU + REWM4 weeks➀He 2015 (83)30/3043.5 ± 9.8 44.2 ± 10.24.1 ± 2.3 4.2 ± 1.9ACU + WMWM4 weeks➀➄Hui 2012 (84)60/6049.63 ± 6.12 48.65 ± 5.113.54 ± 3.96 3.34 ± 4.21MOX + REWM8 weeks➀➅Lu 2021 (85)40/4038.12 ± 8.28 37.57 ± 7.655.25 ± 3.50 4.77 ± 3.26MOX + CHMWM4 weeks➀➁➂➄Wang 2010 (86)45/4546.5 ± 11.75 46.5 ± 11.756.25 ± 2.88 6.25 ± 2.88ACU + REWM3 weeks➀Li 2016 (87)30/3043.18 ± 11.63 44.82 ± 2.52NR 4.36 ± 2.52WAWM8 weeks➀Zhang 2020 (88)34/3439.3 ± 10.1 38.5 ± 9.94.21 ± 3.03 3.96 ± 2.61WAWM8 weeks➀➁➂➃Wang 2020c (89)40/4038.3 ± 4.3 38.2 ± 4.12.4 ± 0.6 2.3 ± 0.3ACU + CHM + WMWM4 weeks➀➁Wang 2008 (90)80/7844.5 ± 13.25 44.5 ± 12.2519 ± 8 17.75 ± 7.625MOX + CHMWM + RE6 weeks➀Lv 2017b (91)46/4639.78 ± 10.58 40.47 ± 11.363.12 ± 1.31 3.26 ± 1.39MOX + RE + WMWM6 weeks➀➃➄Jia 2015 (92)32/3244 ± 8 40.5 ± 8.254.5 ± 1.75 4 ± 1.5MOX + WMWM8 weeks➀Zhang 2021b (14)52/5032.05 ± 5.08 32.12 ± 5.103.52 ± 1.23 3.28 ± 1.01WA + CHM + WMWM8 weeks➀➃➄Zheng 2020 (93)40/4042.63 ± 10.45 46.70 ± 10.7011.46 ± 3.52 10.63 ± 2.95MOX + REWM4 weeks➀➁➄Li 2024 (94)30/3034.27 ± 8.33 32.07 ± 8.922.42 ± 1.19 3.01 ± 1.13ACU + WMWM8 weeks➀➁➅Xiu 2020 (95)36/3636.10 ± 3.11 35.92 ± 3.132.29 ± 0.79 2.30 ± 0.75MOX + CHM + WMWM8 weeks➀➂➄Zhou 2021 (15)47/4636.52 ± 6.24 35.24 ± 5.458.32 ± 1.16 8.05 ± 1.12WA + CHM + WMWM4 weeks➀➃➄Hua 2022 (96)59/5947.06 ± 4.10 47.11 ± 3.252.68 ± 0.29 2.74 ± 0.35ACU + CHM + WMWM12 weeks➀➁➂➄Wang 2013 (97)45/4543.65 ± 13.58 44.56 ± 15.01NR NRACEWM4 weeks➀Han 2009 (98)50/4040.73 ± 8.1 38.73 ± 7.54.2 ± 1.2 4.1 ± 1.7ACUWM4 weeks➀➅Du 2008a (99)89/8043.61 ± 10.16 41.76 ± 1.34.5 ± 1.4 4.1 ± 1.2AA + CHMWM4 weeks➀➅Zhang 2010 (100)40/4042.64 ± 6.91 38.73 ± 7.523.91 ± 2.3 4.12 ± 1.73ACU + WMWM6 weeks➀➅Du 2008b (101)89/8044.5 ± 11.75 41.5 ± 11.754.3 ± 1.4 4.7 ± 1.4AA + CHMWM4 weeks➀Lin 2023 (102)30/3348 ± 11 47.5 ± 11.2517.5 ± 8.25 15.15 ± 7.43MOXWM12 weeks➀Wang 2012 (103)40/3044 ± 3.27 42 ± 3.317.75 ± 3.63 7.71 ± 3.65MOX + RERE7 weeks➀Duan 2012 (104)320/32045.5 ± 14.75 46 ± 14.59.63 ± 4.69 9.63 ± 4.69ACE + RERE8 weeks➀He 2001 (105)36/3541.5 ± 13.25 41.5 ± 13.2510.09 ± 4.96 10.09 ± 4.96ACU + RERE4 weeks➀Li 2008 (106)32/3134.6 36.56.13 ± 2.94 5.75 ± 2.63ACU + MOX + RERE4 weeks➀➅ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy; T, treatment group; C, control group. Baseline of characteristics of included studies. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy; T, treatment group; C, control group. TABLE 2Descriptions of the included acupuncture and related therapies.Study IDAcupuncture-related therapyAcupointsTreatment scheduleZhao 2012 (34)ACE + RETianshu(ST25) Xiawan(CV10) Shangjuxu(ST37) Guanyuan(CV4) Quchi(LI11) Neiting(ST44)Once per weekZhang 2003 (35)ACUSanjiaoshu(BL22) Dachangshu(BL25)30 min per session, once daily; 10 days per treatment courseWang 2022a (36)ACU + CHM + WMShangjuxu(ST37) Yinlingquan(SP9) Tianshu(ST25) Zhigou(TE6) Neiting(ST44) Dachangshu(BL25) Shuidao(ST28) Wailing(ST26)30 min per session, once daily; 5 days per course with 2-day interval before the nextCheng 2009 (37)MOX + CHM + WMZusanli(ST36) Shangjuxu(ST37) Xiajuxu(ST39) Fenglong(ST40) Shousanli(LI10) Hegu(LI4)10 s per sessionFan 2021 (38)MOX + CHMShenque(CV8)40–45 min per session, once daily; 7 days per treatment courseZhou 2008 (39)EA + MOX + WMTianshu(ST25) Zhongwan(CV12) Qihai(CV6) Zusanli(ST36) Shangjuxu(ST37) Yinlingquan(SP9)30 min per session, once daily; 10 days per course with 2-day intervalXu 2022 (40)MOX + CHMTianshu(ST25) Zhongwan(CV12) Pishu(BL20) Huiyang(BL35)30 min per session, once per weekZhao 2019 (41)MOXShenque(CV8)1.5 h per session, twice weeklyYang 2017 (42)MOXPishu(BL20) Zhongwan(CV12) Zusanli(ST36) Dachangshu(BL25) Tianshu(ST25) Shangjuxu(ST37)15 min per session, once dailyHe 2021 (43)MOX + REDachangshu(BL25) Tianshu(ST25) Shangjuxu(ST37)Once daily; 10 days per course with 2-day interval before the nextZhao 2018 (44)ACU + CHMTianshu(ST25) Shangjuxu(ST37)30 min per session, once daily; 6 days treatment, 1 day restZhu 2003 (45)ACEZhongwan(CV12) Zusanli(ST36) Tianshu(ST25)Once every 2 weeksSun 2017 (46)MOXShenque(CV8)2 h per sessionMa 1997 (47)ACUTianshu(ST25) Zhongwan(CV12) Guanyuan(CV4) Zusanli(ST36) Taichong(LR3) Dachangshu(BL25) Shenshu(BL23) Shangliao(BL31) Ciliao(BL32)30 min per session, once dailyWang 2006 (48)MOXShenque(CV8)Once daily; 10-day course with 3-day interval before the nextLi 2006 (49)ACEDachangshu(BL25) Zusanli(ST36) Shangjuxu(ST37)Not reportedKang 2022 (50)ACU + CHMZhongwan(CV12) Xiawan(CV10) Qihai(CV6) Guanyuan(CV4) Daheng(SP15) Wailing(ST26) Huaroumen(ST24)30 min per session, three times per weekWu 2015 (51)ACU + MOX + CHMZhongwan(CV12) Xiawan(CV10) Shenque(CV8) Tianshu(ST25) Guilai(ST27) Qihai(CV6) Guanyuan(CV4) Zusanli(ST36) Yinlingquan(SP9)ACU: 30 min/session, once daily, 10-day course; MOX: every other dayZhang 2021a (52)WA + WMPishu(BL20) Zhongwan(CV12) Zusanli(ST36) Tianshu(ST25) Taibai(SP3) Shangjuxu(ST37) Sanyinjiao(SP6) Guanyuan(CV4)20 min per session, five times per week; 10 days per courseGong 2020 (53)ACEZusanli(ST36) Guanyuan(CV4) Pishu(BL20)Not reportedFeng 2020 (54)ACUGuanyuan(CV4) Qihai(CV6) Changqiang(GV1) Dachangshu(BL25) Tianshu(ST25)20 min per session, once dailyZu 2017 (55)MOX + RE + WMDachangshu(BL25) Pishu(BL20) Shangjuxu(ST37) Xiajuxu(ST39) Tianshu(ST25)Saturating desensitization moxibustion dose, once daily; 14-day course, 2–3 day intervalLv 2017a (56)MOX + CHM + WMDachangshu(BL25) Pishu(BL20) Shangjuxu(ST37) Xiajuxu(ST39) Tianshu(ST25)Saturating moxibustion dose, once daily; 14-day courseGuo 2016 (57)ACU + MOX + WMShenshu(BL23) Pishu(BL20) Dachangshu(BL25) Weishu(BL21) Gongsun(SP4) Tianshu(ST25) Zusanli(ST36) Taixi(KI3) Zhongwan(CV12) Guanyuan(CV4)ACU: 30 min/session, once daily; MOX: 5 moxa cones per acupoint, once daily; 10-day course with 2-day intervalChen 2004 (58)ACEDachangshu(BL25) Tianshu(ST25) Zusanli(ST36)Once per monthChang 2017 (59)MOX + RE + WMShenque(CV8)40 min per session, once dailyWang 2020a (60)EA + CHM + WMZhongwan(CV12) Tianshu(ST25) Zusanli(ST36) Yinlingquan(SP9) Pishu(BL20) Taichong(LR3)30 min per session, once daily; 4-week treatment courseXu 2009 (61)ACU + CHMShangjuxu(ST37) Xiajuxu(ST39) Yinlingquan(SP9) Gongsun(SP4) Tianshu(ST25) Hegu(LI4) Quchi(LI11)30–40 min per session, once dailyGu 2016 (62)MOX + CHMShenque(CV8) Mingmen(GV4) Guanyuan(CV4) Zhongwan(CV12) Zusanli(ST36) Tianshu(ST25) Dachangshu(BL25)Eight moxa cones per point, twice dailyZhang 2022 (13)EA + WMPishu(BL20) Zhongwan(CV12) Zusanli(ST36) Tianshu(ST25) Taibai(SP3) Shangjuxu(ST37) Sanyinjiao(SP6) Guanyuan(CV4)20 min per session, once daily; 5-day course with 2-day intervalXie 2019 (63)ACU + CHMPishu(BL20) Guanyuan(CV4) Weishu(BL21) Tianshu(ST25) Zhongwan(CV12) Zusanli(ST36) Qihai(CV6) Dachangshu(BL25) Gongsun(SP4)20–30 min per session, once daily; 1-week treatment courseShen 2019 (64)MOX + WMZhongwan(CV12) Tianshu(ST25) Guanyuan(CV4) Shangjuxu(ST37)Two moxa cones per point, once daily; 12-day course with 3-day intervalShen 2012 (65)ACUZhongwan(CV12) Tianshu(ST25) Guanyuan(CV4) Zusanli(ST36) Shenque(CV8)30 min per session, once daily; 10-day course with 7-day intervalZong 2015 (66)ACEZhongwan(CV12) Zusanli(ST36) Tianshu(ST25)Once every 2 weeksDu 2008 (67)ACU + RE + CHMZusanli(ST36) Shangjuxu(ST37) Xiajuxu(ST39)30 min per session, once dailyHou 2018 (68)MOX + WMQihai(CV6) Tianshu(ST25) Zhongwan(CV12) Yinlingquan(SP9) Shangjuxu(ST37)Burn moxa fully per session, once daily; 15-day course with 3-day intervalYe 2024 (69)ACU + CHMTianshu(ST25) Quchi(LI11) Shangjuxu(ST37)Two to three times per weekWang 2022b (70)ACUDachangshu(BL25) Tianshu(ST25)30 min per session, once dailyDu 2007 (71)AA + CHMSpleen(MA-IC 3) Large Intestine(MA-IC 5) Endocrine(MA-AT 1) Sympathetic(MA-AH 7) Subcortex(MA-AT 4)Press 3–5 times daily; 10–20 presses per acupointCong 2018 (72)ACU + CHMDachangshu(BL25) Shenque(CV8) Tianshu(ST25) Shangjuxu(ST37) Sanyinjiao(SP6) Pishu(BL20) Hegu(LI4) Xiajuxu(ST39) Zusanli(ST36) Guanyuan(CV4) Quchi(LI11) Neiting(ST44)15 min per session, once daily; 5-day course with 2-day intervalZhou 2003 (73)MOXZhongwan(CV12) Tianshu(ST25) Zusanli(ST36)5–7 moxa cones until skin reddens, once daily; 10-day courseGe 2014 (74)EA + WMGanshu(BL18) Pishu(BL20) Dachangshu(BL25) Shenshu(BL23) Ciliao(BL32) Tianshu(ST25) Qihai(CV6) Guanyuan(CV4) Shangjuxu(ST37) Sanyinjiao(SP6) Taichong(LR3)30 min per session, once daily; 5-day course with 2–3 day intervalZhang 2012 (75)ACU + REPishu(BL20) Zhongwan(CV12) Tianshu(ST25) Zusanli(ST36) Shangjuxu(ST37)30 min per session, once daily; 2-week treatment courseChen 2013 (76)MOX + RE + WMTianshu(ST25) Shenque(CV8) Guanyuan(CV4) Zhongwan(CV12) Zusanli(ST36) Qihai(CV6) Pishu(BL20) Shangjuxu(ST37) Yinlingquan(SP9)Not reportedXu 2023 (77)ACU + CHM + REYinbai(SP1) Shaoshang(LU11)20 min per session, every other dayWang 2020b (78)ACU + CHM + WMDachangshu(BL25) Shangjuxu(ST37) Xiajuxu(ST39) Shenque(CV8) Tianshu(ST25) Zusanli(ST36)15 min per session, once daily; 5-day course with 2-day intervalTeng 2014 (79)EA + RE + WMZhongwan(CV12) Tianshu(ST25) Guanyuan(CV4) Zusanli(ST36) Sanyinjiao(SP6)Not reportedZhang 2009 (80)ACU + CHMScalp Acupuncture Stomach Zone Scalp Acupuncture Intestinal Zone5–10 min per session, once dailyCao 2001 (81)ACU + REPishu(BL20) Zhangmen(LR13) Tianshu(ST25) Zusanli(ST36) Zhongwan(CV12) Guanyuan(CV4) Mingmen(GV4) Gongsun(SP4)20 min per session, once dailyBao 2014 (82)ACU + REGuanyuan(CV4) Tianshu(ST25) Zusanli(ST36) Yinlingquan(SP9) Sanyinjiao(SP6)20 min per session, once dailyHe 2015 (83)ACU + WMTianshu(ST25) Qihai(CV6) Guanyuan(CV4) Hegu(LI4) Shangjuxu(ST37) Sanyinjiao(SP6)Once daily; 5-day course with 2-day intervalHui 2012 (84)MOX + REShenque(CV8) Zhongwan(CV12) Zusanli(ST36)Three moxa cones per acupoint, once dailyLu 2021 (85)MOX + CHMShenque(CV8)20 min per session, once every 2 daysWang 2010 (86)ACU + RETianshu(ST25) Daheng(SP15) Zusanli(ST36) Shenque(CV8)30 min per session, once daily; 7-day course with 1–2 day intervalLi 2016 (87)WATianshu(ST25) Qihai(CV6) Guanyuan(CV4) Changqiang(GV1) Dachangshu(BL25) Zusanli(ST36) Sanyinjiao(SP6)20 min per session, once every 2 daysZhang 2020 (88)WAPishu(BL20) Zhongwan(CV12) Zusanli(ST36) Tianshu(ST25) Taibai(SP3) Shangjuxu(ST37) Sanyinjiao(SP6) Guanyuan(CV4)20 min per session, 5 times per week; 10 sessions per courseWang 2020c (89)ACU + CHM + WMQuchi(LI11) Hegu(LI4) Tianshu(ST25) Neiting(ST44) Shangjuxu(ST37)15–20 min per session, once daily; 5-day course with 2-day intervalWang 2008 (90)MOX + CHMShenque(CV8) Zusanli(ST36) Tianshu(ST25) Shangjuxu(ST37)20 min per session, once daily; 10-day course with 2-day intervalLv 2017b (91)MOX + RE + WMDachangshu(BL25) Pishu(BL20) Shangjuxu(ST37) Xiajuxu(ST39) Tianshu(ST25)15 min per session, once dailyJia 2015 (92)MOX + WMZhongji(CV3) Guanyuan(CV4) Qihai(CV6) Tianshu(ST25) Daheng(SP15) Dachangshu(BL25) Zusanli(ST36) Shangjuxu(ST37) Sanyinjiao(SP6) Taichong(LR3)Once dailyZhang 2021b (14)WA + CHM + WMZhongwan(CV12) Guanyuan(CV4) Qihai(CV6) Zusanli(ST36) Tianshu(ST25) Yinlingquan(SP9)Once daily; 6-day course with 1-day intervalZheng 2020 (93)MOX + REShenque(CV8)30 min per session, once daily; 7-day courseLi 2024 (94)ACU + WMTianshu(ST25)20 min per session, once daily; 5-day course with 2-day intervalXiu 2020 (95)MOX + CHM + WMZhongwan(CV12) Guanyuan(CV4) Qihai(CV6) Tianshu(ST25)30–40 min per session, once dailyZhou 2021 (15)WA + CHM + WMGuanyuan(CV4) Zhongwan(CV12) Tianshu(ST25) Zusanli(ST36) Shangjuxu(ST37) Pishu(BL20) Shenshu(BL23) Dachangshu(BL25)30 min per session, once daily; 5 days per course with 2-day interval before the nextHua 2022 (96)ACU + CHM + WMQuchi(LI11) Tianshu(ST25) Guanyuan(CV4) Shangjuxu(ST37) Zusanli(ST36)30 min per session, once daily; 5 days per course with 2-day interval before the nextWang 2013 (97)ACEPishu(BL20) Weishu(BL21) Dachangshu(BL25)Once every 15 daysHan 2009 (98)ACUScalp Acupuncture Stomach Zone Scalp Acupuncture Intestinal Zone5–10 min per session, once dailyDu 2008a (99)AA + CHMSpleen(MA-IC 3) Large Intestine(MA-IC 5) Endocrine(MA-AT 1) Sympathetic(MA-AH 7) Subcortex(MA-AT 4)Press 3–5 times daily; 10–20 presses per acupointZhang 2010 (100)ACU + WMScalp Acupuncture Stomach Zone Scalp Acupuncture Intestinal Zone5–10 min per session, once daily; 20-day course with 2-day intervalDu 2008b (101)AA + CHMSpleen(MA-IC 3) Large Intestine(MA-IC 5) Endocrine(MA-AT 1) Sympathetic(MA-AH 7) Subcortex(MA-AT 4)Press 3–5 times daily; 10–20 presses per acupointLin 2023 (102)MOXQihai(CV6) Tianshu(ST25) Shangjuxu(ST37) Xiajuxu(ST39)Three times per weekWang 2012 (103)MOX + REShenque(CV8)6–8 hDuan 2012 (104)ACE + RETianshu(ST25) Dachangshu(BL25) Guanyuan(CV4) Zhongwan(CV12) Zusanli(ST36) Yinlingquan(SP9)Once every 2 weeks; 14-day course with 7-day intervalHe 2001 (105)ACU + REZusanli(ST36) Shangjuxu(ST37) Xiajuxu(ST39)30 min per session, once daily; 14-day course with 3-day intervalLi 2008 (106)ACU + MOX + REZhongwan(CV12) Qihai(CV6) Zusanli(ST36) Sanyinjiao(SP6) Hegu(LI4) Dachangshu(BL25) Tianshu(ST25) Shangjuxu(ST37)30 min per sessionACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine. Descriptions of the included acupuncture and related therapies. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine. Risk of bias, certainty of evidence, and consistency A total of 76 RCTs were included in this study. 32 studies (42.1%) were rated as high risk of bias due to unclear randomization. 76 studies (100%) did not describe any blinding. Considering the characteristics of the intervention, the risk of bias was judged to be some concerns. 76 studies (100%) had a low risk of missing outcome data and outcome measurement bias. There was no evidence of selective reporting or other potential sources of bias. Overall, 41 studies (57.9%) were rated as some concerns, while 35 studies (42.1%) were rated as high risk. A summary of the risk assessment is provided in Supplementary Material 4 and illustrated in Figure 2. As no closed loops were formed between the included interventions, consistency testing was deemed unnecessary. The consistency model demonstrated good agreement across all comparisons, with no significant inconsistency observed between direct and indirect evidence. Heterogeneity was assessed using τ2, and the results showed low heterogeneity in dichotomous variables, indicating high consistency between studies. For continuous data, there was moderate to high heterogeneity (Supplementary Material 5). Assessment of risk of bias. Network meta-analysis results Network plots Among the 76 included RCTs, 75 studies reported total effective rate, involving 10 acupuncture-related therapies; 9 studies reported Mayo score, involving 5 acupuncture-related therapies; 12 studies reported Baron endoscopic score, involving 4 acupuncture-related therapies; 13 studies reported IL-6 levels, involving 5 acupuncture-related therapies; 18 studies reported TNF-α levels, involving 5 acupuncture-related therapies; and 15 studies reported recurrence rate, involving 6 acupuncture-related therapies. Node size reflects the number of participants, while the thickness of the connecting lines represents the number of randomized trials (see Figure 3 and Supplementary Material 6). Network plot for different interventions. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, Electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy. Total effective rate The total effective rate was defined as the proportion of patients achieving an “effective” or “improved” outcome. An “effective” outcome required the resolution of symptoms and an essentially normal mucosa on colonoscopy, whereas an “improved” outcome was defined by the presence of intermittent symptoms and only mild inflammatory changes. This network meta-analysis evaluated the effectiveness of various acupuncture-related interventions in improving clinical symptoms in patients. The results indicated that all ten acupuncture-related interventions significantly improved total effective rate compared with control groups. Among these, AA + CHM (RR 1.71, 95% CI: 1.47, 1.99, SUCRA = 99.9%) showed a relatively greater benefit, followed by ACU (RR 1.37, 95% CI: 1.22, 1.54, SUCRA = 84.8%) and WA (RR 1.34, 95% CI: 1.11, 1.61, SUCRA = 75.1%). Indirect comparisons among acupuncture-related therapies indicated that AA + CHM showed superior efficacy over all other interventions, and ACU was superior to ACU-CT (RR 1.12, 95% CI: 1.01, 1.24), MOX-CT (RR 1.11, 95% CI: 1.00, 1.23), WA-CT (RR 1.13, 95% CI: 1.00, 1.28), and ACE (RR 1.14, 95% CI: 1.02, 1.28) (Table 3). To explore the relative efficacy of each intervention, we calculated SUCRA values (Figure 4; Supplementary Material 7). TABLE 3League table of total effective rate.AA+CHM1.25 (1.06, 1.46)ACU1.40 (1.22, 1.60)1.12 (1.01, 1.24)ACU-CT1.34 (1.15, 1.57)1.08 (0.95, 1.23)0.96 (0.87, 1.06)MOX1.38 (1.20, 1.59)1.11 (1.00, 1.23)0.99 (0.93, 1.05)1.03 (0.93, 1.14)MOX-CT1.28 (1.04, 1.58)1.02 (0.85, 1.24)0.91 (0.77, 1.08)0.95 (0.79, 1.15)0.92 (0.78, 1.10)WA1.41 (1.21, 1.64)1.13 (1.00, 1.28)1.01 (0.92, 1.10)1.05 (0.93, 1.18)1.02 (0.93, 1.12)1.11 (0.92, 1.33)WA-CT1.42 (1.23, 1.65)1.14 (1.02, 1.28)1.02 (0.94, 1.10)1.06 (0.95, 1.19)1.03 (0.94, 1.12)1.11 (0.93, 1.33)1.01 (0.91, 1.12)ACE1.32 (1.12, 1.56)1.06 (0.92, 1.22)0.95 (0.86, 1.04)0.99 (0.86, 1.13)0.96 (0.85, 1.07)1.04 (0.85, 1.26)0.94 (0.82, 1.07)0.93 (0.82, 1.06)ACE-CT1.33 (1.13, 1.56)1.06 (0.93, 1.22)0.95 (0.85, 1.05)0.99 (0.87, 1.13)0.96 (0.86, 1.07)1.04 (0.86, 1.26)0.94 (0.83, 1.06)0.93 (0.83, 1.05)1.00 (0.87, 1.16)EA-CT1.62 (1.37, 1.90)1.30 (1.13, 1.49)1.15 (1.05, 1.27)1.20 (1.05, 1.38)1.17 (1.05, 1.31)1.27 (1.04, 1.54)1.15 (1.01, 1.30)1.14 (1.01, 1.28)1.22 (1.07, 1.40)1.22 (1.06, 1.40)CHM1.65 (1.41, 1.94)1.33 (1.16, 1.51)1.18 (1.09, 1.29)1.23 (1.08, 1.40)1.20 (1.08, 1.32)1.29 (1.07, 1.56)1.17 (1.04, 1.32)1.16 (1.04, 1.30)1.25 (1.18, 1.32)1.25 (1.09, 1.42)1.02 (0.90, 1.16)RE1.65 (1.45, 1.88)1.32 (1.20, 1.45)1.18 (1.13, 1.22)1.23 (1.12, 1.34)1.19 (1.13, 1.25)1.29 (1.09, 1.52)1.17 (1.08, 1.26)1.16 (1.08, 1.24)1.24 (1.12, 1.38)1.24 (1.13, 1.37)1.02 (0.92, 1.13)1.00 (0.91, 1.09)WM1.71 (1.47, 1.99)1.37 (1.22, 1.54)1.22 (1.12, 1.33)1.27 (1.13, 1.44)1.24 (1.15, 1.33)1.34 (1.11, 1.61)1.21 (1.08, 1.36)1.20 (1.08, 1.34)1.29 (1.13, 1.47)1.29 (1.14, 1.46)1.06 (0.93, 1.20)1.03 (0.92, 1.16)1.04 (0.96, 1.13)WM+RECU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, 1.25 (1.06, 1.46) indicates that AA + CHM significantly outperforms ACU. League table of total effective rate. CU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, 1.25 (1.06, 1.46) indicates that AA + CHM significantly outperforms ACU. SUCRA plot for total effective rate. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; ACE, acupoint catgut embedding; EA, Electroacupuncture; AA, auricular acupressure; CHM, Chinese Herbal Medicine; RE, retention enema; WM, western medicine; CT, combination therapy. Mayo score Network meta-analysis results based on Mayo score showed that ACU-CT (SMD-4.85, 95% CI: –6.66, –3.05, SUCRA = 97.5%) was associated with the greatest reduction in Mayo score compared with WM, followed by WA (SMD-2.89, 95% CI: –4.68, –1.09, SUCRA = 68.4%), WA-CT (SMD-2.79, 95% CI: –4.57, –1.02, SUCRA = 65.8%), and MOX-CT (SMD-1.82, 95% CI: –2.60, –1.04, SUCRA = 43.7%). Indirect comparisons among five acupuncture-related therapies, ACU-CT was more effective than MOX (SMD-4.14, 95% CI: –6.65, –1.63) and MOX-CT (SMD-3.04, 95% CI: –5.00, –1.07) (Table 4). To explore the relative efficacy of each intervention, we calculated SUCRA values (Figure 5; Supplementary Material 7). TABLE 4League table of Mayo score.ACU-CT−4.14 (−6.65, −1.63)MOX−3.04 (−5.00, −1.07)1.10 (−0.80, 3.01)MOX-CT−1.97 (−4.52, 0.58)2.17 (−0.33, 4.67)1.07 (−0.89, 3.03)WA−2.06 (−4.59, 0.47)2.08 (−0.40, 4.56)0.98 (−0.96, 2.92)−0.09 (−2.62, 2.43)WA-CT−4.85 (−6.66, −3.05)−0.71 (−2.45, 1.02)−1.82 (−2.60, −1.04)−2.89 (−4.68, −1.09)−2.79 (−4.57, −1.02)WMACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, –4.14 (−6.65,–1.63) indicates that ACU-CT significantly outperforms MOX. League table of Mayo score. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, –4.14 (−6.65,–1.63) indicates that ACU-CT significantly outperforms MOX. SUCRA plot for Mayo score. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; WM, western medicine; CT, combination therapy. Baron endoscopy score Network meta-analysis results based on baron endoscopy score indicated that only ACU-CT led to a statistically significant reduction compared with WM (SMD-2.31, 95% CI: –3.81, –0.81, SUCRA = 84.1%). Other interventions showed a downward trend, but without statistical significance (Table 5). To explore the relative efficacy of each intervention, we calculated SUCRA values (Figure 6; Supplementary Material 7). TABLE 5League table of Baron endoscopy score.ACU-CT−1.60 (−5.56, 2.37)MOX−1.70 (−4.29, 0.89)−0.10 (−4.34, 4.13)MOX-CT−0.35 (−4.32, 3.63)1.25 (−3.94, 6.44)1.36 (−2.88, 5.59)WA−3.06 (−6.74, 0.61)−1.47 (−6.87, 3.94)−1.36 (−5.86, 3.14)−2.72 (−8.13, 2.70)RE−2.31 (−3.81, −0.81)−0.71 (−4.38, 2.95)−0.61 (−2.72, 1.50)−1.96 (−5.64, 1.71)0.75 (−3.22, 4.72)WMACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; RE, retention enema; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, –2.31 (−-3.81, –0.81) indicates that ACU-CT significantly outperforms WM. League table of Baron endoscopy score. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; RE, retention enema; WM, western medicine; CT, combination therapy. Cells highlighted in blue represent comparisons in which the row intervention is significantly more effective than the column intervention. For instance, –2.31 (−-3.81, –0.81) indicates that ACU-CT significantly outperforms WM. SUCRA plot for Baron endoscopy score. ACU, acupuncture; MOX, moxibustion; WA, warm acupuncture; RE, retention enema; WM, western medicine; CT, combination therapy. IL-6 Network meta-analysis results based on IL-6 showed that among all interventions compared with WM, WA exhibited the most significant reduction (SMD-3.10, 95% CI: –4.56, –1.65, SUCRA = 96.1%), followed by ACE (SMD-2.13, 95% CI: –3.49, –0.77, SUCRA = 77%), WA-CT (SMD-1.76, 95% CI: –2.54, –0.98, SUCRA = 69.2%), and MOX-CT (SMD-1.18, 95% CI: –1.85, –0.50, SUCRA = 49%). Compared with WM + RE, WA (SMD-2.85, 95% CI: –4.71, –0.99, SUCRA = 96.1%), WA-CT (SMD-1.51, 95% CI: –2.90, –0.11, SUCRA = 69.2%), and ACE (SMD-1.88, 95% CI: –3.66, –0.09, SUCRA = 77%) also demonstrated significantly greater reductions. In indirect comparisons, WA was superior to ACU-CT (SMD 2.24, 95% CI: 0.51, 3.98) and MOX-CT (SMD 1.93, 95% CI: 0.32, 3.54). Other comparisons showed a trend of improvement but without statistical significance (Supplementary Material 8). To explore the relative efficacy of each intervention, we calculated SUCRA values (Supplementary Material 7). TNF-α The network meta-analysis showed that WA-CT was the most effective intervention in reducing TNF-α levels compared with WM (SMD-2.32, 95% CI: –4.54, –0.10, SUCRA = 76.8%), followed by MOX-CT (SMD-2.00, 95% CI: –3.19, –0.81, SUCRA = 71.7%) and ACU-CT (SMD-1.64, 95% CI: –3.04, –0.24, SUCRA = 61.4%). However, no statistically significant differences were observed among the acupuncture-related interventions (Supplementary Material 8). To explore the relative efficacy of each intervention, we calculated SUCRA values (Supplementary Material 7). Recurrence rate For recurrence rate, ACU significantly reduced recurrence compared with WM (OR 0.12, 95% CI: 0.03, 0.43, SUCRA = 89.3%), followed by ACE (OR 0.17, 95% CI: 0.04, 0.77, SUCRA = 78.1%), ACU-CT (OR 0.21, 95% CI: 0.08, 0.57, SUCRA = 76.6%), and MOX-CT (OR 0.21, 95% CI: 0.10, 0.44, SUCRA = 75.4%). Compared with WM + RE, ACU (OR 0.15, 95% CI: 0.03, 0.65, SUCRA = 89.3%) and MOX-CT (OR 0.26, 95% CI: 0.09, 0.76, SUCRA = 75.4%) also showed superior efficacy. Compared with RE, only ACU-CT (OR 0.23, 95% CI: 0.06, 0.84, SUCRA = 76.6%) showed a statistically significant advantage. No significant differences were found among acupuncture-related interventions (Supplementary Material 8). To explore the relative efficacy of each intervention, we calculated SUCRA values (Supplementary Material 7). Adverse events It is worth noting that there were 13 RCTs reported adverse events, involving 125 patients. Among them, 88 adverse events occurred in the control groups and 37 in the treatment groups (Supplementary Material 9). There were no serious adverse effects in any of the studies. The available data suggest that acupuncture-related therapies are associated with a lower incidence and severity of adverse events compared to control group, indicating a potentially better safety profile. Publication bias The potential for publication bias was assessed through visual inspection of funnel plots for all outcomes. The funnel plots for the total effective rate and recurrence rate presented a generally symmetrical appearance, suggesting a low likelihood of publication bias. Similarly, the distributions for IL-6 and TNF-α also showed a broadly symmetrical pattern, indicating that publication bias for these inflammatory markers was not prominent. In contrast, the funnel plots for the Mayo score and Baron endoscopy score displayed some degree of asymmetry. This observed asymmetry may point to the possible presence of publication bias or reflect underlying clinical and methodological heterogeneity among the included studies for these specific outcomes. Overall, while minor asymmetries were present for some measures, the funnel plot analysis did not provide clear evidence of substantial publication bias across the network meta-analysis. See Supplementary Material 10 for details. Quality of evidence assessment The overall certainty of evidence for the outcomes evaluated was moderate to low. Total effective rate was graded as moderate certainty, primarily limited by a serious risk of bias across studies due to inadequate reporting of randomization and allocation concealment, as well as the inherent challenges in blinding participants and practitioners. For Mayo score, Baron endoscopy score, and adverse events, the certainty was low. These ratings were influenced by serious risks of bias, considerable heterogeneity, and imprecision resulting from limited sample sizes and wide confidence intervals. Additionally, potential publication bias could not be excluded, given the predominance of positive results and regional concentration of studies (see Table 6 for details). TABLE 6Assessment of quality of evidence.OutcomeParticipants (studies)Risk of biasInconsistencyIndirectnessImprecisionPublication biasCertainty (GRADE)Total effective rate7,404 (75 RCTs)Serious ➀Not seriousNot seriousNot seriousPossible ➁⊕⊕⊕○ ModerateMayo score734 (9 RCTs)Serious ➀Serious ➁Not seriousSerious ➃Possible ➁⊕⊕○○ LowBaron endoscopy score1,124 (12 RCTs)Serious ➀Serious ➄Not seriousSerious ➃Possible ➁⊕⊕○○ LowAdverse events1,236 (13 RCTs)Serious ➅Not seriousNot seriousSerious ➃Possible ➁⊕⊕○○ Low➀ The majority of the included trials only mentioned “randomization” without describing the specific random allocation sequence generation or allocation concealment methods. Due to the nature of the acupuncture interventions, performance bias was likely high as blinding of practitioners and participants was not feasible. Many trials also did not report blinding of outcome assessors. ➁ Publication bias cannot be ruled out, as the funnel plot’s symmetry may be misleading given the field’s propensity for positive results and the overwhelming predominance of Chinese studies, introducing potential language and geographic bias. ➂ Considerable heterogeneity (τ2 = 0.71) was observed, reflecting inconsistent effects on the Mayo score across the included trials. ➃ The total sample size for this outcome is limited, resulting in a wide 95% confidence interval for the pooled effect estimate and imprecise results. ➄ The moderate-to-high heterogeneity (τ2 = 0.343) reflects substantial inconsistency across studies. ➅ Most studies did not systematically monitor or report adverse events, leading to an underestimation of their incidence. Assessment of quality of evidence. ➀ The majority of the included trials only mentioned “randomization” without describing the specific random allocation sequence generation or allocation concealment methods. Due to the nature of the acupuncture interventions, performance bias was likely high as blinding of practitioners and participants was not feasible. Many trials also did not report blinding of outcome assessors. ➁ Publication bias cannot be ruled out, as the funnel plot’s symmetry may be misleading given the field’s propensity for positive results and the overwhelming predominance of Chinese studies, introducing potential language and geographic bias. ➂ Considerable heterogeneity (τ2 = 0.71) was observed, reflecting inconsistent effects on the Mayo score across the included trials. ➃ The total sample size for this outcome is limited, resulting in a wide 95% confidence interval for the pooled effect estimate and imprecise results. ➄ The moderate-to-high heterogeneity (τ2 = 0.343) reflects substantial inconsistency across studies. ➅ Most studies did not systematically monitor or report adverse events, leading to an underestimation of their incidence. Discussion Principal findings This systematic review and network meta-analysis provides a comprehensive hierarchy of the relative efficacy and safety of various acupuncture-related therapies for UC, based on 76 RCTs. Our findings suggest several potentially important clinical implications: For total effective rate: AA + CHM demonstrated the highest probability of being the best intervention. This highlights the potent synergistic effect that can be achieved by combining internal herbal medicine with external acupoint stimulation. For total effective rate: AA + CHM demonstrated the highest probability of being the best intervention. This highlights the potent synergistic effect that can be achieved by combining internal herbal medicine with external acupoint stimulation. For promoting mucosal healing: Baron score assesses the extent of UC disease, and Mayo score assesses mucosal healing. Intestinal mucosal healing is considered to be a key goal of UC treatment, which is closely related to reducing the recurrence rate, reducing the risk of colectomy, and preventing colorectal cancer (107). ACU-CT was significantly better than the control group in improving colonoscopic scores, indicating that acupuncture combined therapy could promote the healing of the damaged intestinal mucosa and control the progression of the disease. For promoting mucosal healing: Baron score assesses the extent of UC disease, and Mayo score assesses mucosal healing. Intestinal mucosal healing is considered to be a key goal of UC treatment, which is closely related to reducing the recurrence rate, reducing the risk of colectomy, and preventing colorectal cancer (107). ACU-CT was significantly better than the control group in improving colonoscopic scores, indicating that acupuncture combined therapy could promote the healing of the damaged intestinal mucosa and control the progression of the disease. For reducing systemic inflammation: TNF-α and IL-6 are key cytokines involved in inflammatory and autoimmune processes and their overexpression is closely related to inflammatory damage to the intestinal mucosa (108). Our quantitative findings provide specific support for the anti-inflammatory potential of acupuncture therapies. The results showed that WA and WA-CT were the most effective interventions for lowering key pro-inflammatory cytokines IL-6 and TNF-α, respectively. This indicates that the thermal stimulation characteristic of warm acupuncture may have a specific and powerful anti-inflammatory effect, modulating the underlying immune dysregulation in UC. For reducing systemic inflammation: TNF-α and IL-6 are key cytokines involved in inflammatory and autoimmune processes and their overexpression is closely related to inflammatory damage to the intestinal mucosa (108). Our quantitative findings provide specific support for the anti-inflammatory potential of acupuncture therapies. The results showed that WA and WA-CT were the most effective interventions for lowering key pro-inflammatory cytokines IL-6 and TNF-α, respectively. This indicates that the thermal stimulation characteristic of warm acupuncture may have a specific and powerful anti-inflammatory effect, modulating the underlying immune dysregulation in UC. For preventing disease relapse: ACU alone showed the greatest advantage in reducing recurrence rates. This remarkable finding suggests that conventional acupuncture may possess long-term regulatory effects that help sustain remission, potentially by restoring physiological balance and regulating the gut-brain axis. For preventing disease relapse: ACU alone showed the greatest advantage in reducing recurrence rates. This remarkable finding suggests that conventional acupuncture may possess long-term regulatory effects that help sustain remission, potentially by restoring physiological balance and regulating the gut-brain axis. Safety profile: The available data on adverse events consistently indicated that acupuncture-related therapies were associated with a lower incidence and severity of adverse events compared to conventional pharmaceutical treatments. This favorable safety profile positions these therapies as valuable complementary or alternative options, especially for patients intolerant to or seeking to reduce the burden of long-term drug use. Safety profile: The available data on adverse events consistently indicated that acupuncture-related therapies were associated with a lower incidence and severity of adverse events compared to conventional pharmaceutical treatments. This favorable safety profile positions these therapies as valuable complementary or alternative options, especially for patients intolerant to or seeking to reduce the burden of long-term drug use. Acupoint analysis revealed that three studies using auricular acupressure all selected Spleen (MA-IC 3), Large Intestine (MA-IC 5), Endocrine (MA-AT 1), Sympathetic (MA-AH 7), and Subcortex (MA-AT 4). 2 studies using scalp acupuncture were used in both the stomach zone and intestinal zone. High-frequency acupoint analysis showed that Tianshu (ST25), Zusanli (ST36), Shangjuxu (ST37), and Zhongwan (CV12) were the most commonly used points. Tianshu is the Front-Mu point of the large intestine, which has the effect of regulating the gastrointestinal function and restoring normal intestinal motility and transformation. It is frequently used to relieve symptoms of bowel dysfunction such as abdominal pain, diarrhea, and constipation in UC patients, and is also a commonly selected point in experimental animal models of acupuncture for UC (109, 110). Therefore, the improvements in Mayo score and endoscopic outcomes observed in our study may be mechanistically underpinned by the widespread use of these pivotal acupoints, which are believed to exert multi-target effects. Zusanli is the Lower He-Sea point of the stomach, is known for harmonizing the stomach and intestines, regulating Qi of the Yangming meridian, enhancing immunity, and improving systemic function. Shangjuxu is the Lower He-Sea point of the large intestine, which has the effect of regulating the stomach and intestines, regulating qi and dissolving stagnation. Zhongwan is the Front-Mu point of the stomach, which has the effect of soothing the middle coke qi machine, and reducing stomach inversion and relieving pain. Acupuncture can regulate immune balance, reduce the expression of pro-inflammatory factors, and repair the intestinal mucosal barrier function, so it is effective for UC (111, 112). The differences in the therapeutic efficacy of various acupuncture-related therapies for UC may be attributed to their distinct stimulation modalities, mechanisms of action, and intervention characteristics. Traditional manual acupuncture uses physical stimulation on the body surface as a method to regulate the immune response by activating the three anti-inflammatory pathways, including the cholinergic anti-inflammatory pathway, splenic sympathetic anti-inflammatory pathway, and the hypothalamic–pituitary–adrenal (HPA) axis (113). Electroacupuncture combines millineedle stimulation with electrical stimulation to enhance the amount of stimulation to acupuncture points, which can jointly stimulate the vagus nerve, activate the cholinergic anti-inflammatory pathway, and inhibit the expression of pro-inflammatory factors, thereby alleviating the inflammatory response of UC (114). Moxibustion stimulates meridian acupuncture points with warmth, strengthens the flow of qi and blood in the body, and regulates the intestinal flora by inhibiting the expression of IL-12 and TNF-α (115). Acupoint catgut embedding involves implanting absorbable sutures into specific acupoints, delivering prolonged and gentle stimulation. This method has been reported to support intestinal microecological balance and immune regulation, offering long-lasting and stable clinical efficacy (116). Auricular acupressure stimulates corresponding reflex points related to the affected internal organs, thereby promoting intestinal peristalsis and enhancing gastrointestinal function. Given the unique features of each intervention in stimulation method, intensity, and therapeutic mechanisms, personalized treatment approaches tailored to patients’ physical constitution and clinical presentation are warranted in future practice. Strengths This study has several notable strengths: (1) The literature search system is comprehensive, the sample size included is sufficient, and the variety of therapies is covered, which enhances the representativeness and stability of the conclusions; (2) The network meta-analysis method was used to achieve direct and indirect comparison between a variety of acupuncture-related therapies, thereby overcoming the limitations of traditional pairwise meta-analysis that are restricted to two-group comparisons. (3) Outcomes included symptom scores, endoscopic scores, serum inflammatory markers and recurrence rate, allowing for a multidimensional evaluation of therapeutic efficacy. (4) Acupuncture-related interventions demonstrated a low incidence of adverse events, indicating a favorable safety profile, highlighting the advantages of the holistic regulatory approach of traditional Chinese medicine. Limitations This study has several limitations: (1) Among the 76 RCTs, some studies only mentioned “randomization” without providing specific details on the randomization method. Moreover, most RCTs did not report blinding procedures or allocation concealment, which may affect the credibility of the risk of bias assessments. (2) Only a limited number of studies reported Baron endoscopic score and Mayo score, which may compromise the stability and generalizability of the analyses. (3) The majority of the included studies were conducted in China, introducing a potential regional bias. Therefore, the international applicability of the findings requires further validation. (4) Due to limitations in the original literature, interventions involving combination therapies (one of which is acupuncture-related therapy) were uniformly categorized as combination therapy, including ACU + MOX + WM, ACU + MOX + CHM, ACU + MOX + RE, etc. Given the diversity of combination therapy strategies, further clarification will be provided in future studies. (5) A small number of included studies did not fully report the details of their treatment schedules. While this does not undermine the primary findings of our network meta-analysis regarding the comparative efficacy of different therapy classes, it highlights a key area for improvement in future trial reporting to enhance reproducibility and clinical translation. Conclusion ACU, MOX, WA, and their combination therapies may represent the most effective treatment for UC. The identified core acupoints provide a standardized basis for clinical practice. The results of this analysis suggest that acupuncture has the potential to serve as a component of the comprehensive management strategy for UC and is expected to gain broader clinical application in the future. Future research should focus on conducting large-sample, high-quality RCTs with longer follow-up periods to confirm the long-term efficacy and to elucidate the specific mechanisms of action behind these distinct acupuncture interventions.